IKZF1 and hematologic disorder: Exhibiting superior efficacy over parallel drugs designed for the same purpose in hematologic malignancies, such as CC-220 and lenalidomide, CC-99282 delivers accelerated, more profound, and longer-lasting IKZF1/3 degradation [144].